查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2026773

肺動脈高壓市場預測至2034年－按產品、類型、給藥途徑、最終用戶和地區分類的全球分析

Pulmonary Arterial Hypertension Market Forecasts to 2034 - Global Analysis By Type, Product, Route of Administration, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球肺動脈高壓市場規模將達到 67 億美元，並在預測期內以 7.4% 的複合年成長率成長，到 2034 年將達到 118 億美元。

肺動脈高壓（PAH）是一種罕見但危險的疾病，其特徵是肺部供血動脈血壓升高。肺動脈壓力升高可導致呼吸困難和心臟衰竭等併發症。目前，肺動脈高壓市場涵蓋多種旨在控制和緩解肺動脈高壓症狀的治療方法，最終目標是改善患者的整體健康和預後。

根據《美國醫療管理雜誌》報道，肺動脈高壓（PAH）是一種罕見疾病，在美國和歐洲，每百萬人中約有15至50人患有此病。特發性、遺傳性及食慾抑制劑誘發的PAH佔所有PAH病例的52.6%。 PAH通常發生於30至60歲的女性。

風險因素增加

肺動脈高壓（PAH）通常與結締組織疾病、先天性心臟疾病和肝病等潛在疾病有關。隨著這些危險因子在全球的發病率不斷上升，PAH的盛行率也增加。此外，久坐的生活方式和接觸環境毒素等生活方式因素也會導致PAH病例的增加。由於PAH在老年人群中更為常見，隨著人口老化，患病風險進一步增加。這些危險因子帶來的負擔日益加重，導致PAH患者人數激增，因此對創新治療方法、藥物介入和醫學進步的需求也日益成長。

治療方案相關的高昂費用

肺動脈高壓 (PAH)治療方法費用高昂是該領域的主要障礙。包括磷酸二酯酶-5 抑制劑、內皮素受體拮抗劑和前列腺環素類似物在內的 PAH 藥物價格昂貴，對患者和醫療系統而言都難以承受。 PAH 診斷和治療的複雜性使得疾病管理的最佳化更具挑戰性，需要專門的醫療基礎設施和專業知識。這些經濟和實際方面的限制阻礙了有效 PAH 治療的開展，凸顯了提供更便利、更經濟的治療方案的必要性。

開發創新治療方法

肺動脈高壓 (PAH) 市場蘊藏著許多機遇，包括新型治療策略和特異性的研發。技術和科學的進步使得人們能夠找到新的、更有效的治療方法來解決 PAH 的根本原因。早期診斷的改進和公眾意識的提高有望擴大患者群體。

治療選擇有限

肺動脈高壓 (PAH) 市場正受到治療選擇匱乏和有效治療方法研發困難的嚴重威脅。由於 PAH 是一種罕見且嚴重的疾病，其複雜的病理生理機制以及對新型作用機制的需求，使得新藥研發極具挑戰性。然而，缺乏多樣化和特異性的治療方案限制了患者的選擇，並可能阻礙 PAH 市場的整體成長。

新冠疫情的影響：

新冠疫情對市場產生了重大影響。封鎖期間，肺動脈高壓（PAH）患者就醫困難。醫療系統的中斷導致PAH患者的診斷和治療啟動延遲。此外，新PAH療法的研發也受到阻礙，影響了前景看好的藥物研發管線。醫療資源的重新分配和經濟的不確定性進一步加劇了PAH市場的壓力。疫情對市場動態和PAH管理的長期影響仍然令人擔憂，需要持續努力應對這些挑戰。

在預測期內，磷酸二酯酶 5 (PDE-5) 抑制劑細分市場預計將佔據最大佔有率。

在整個預測期內，磷酸二酯酶5 (PDE-5) 抑制劑市佔率最大。磷酸二酯酶5 (PDE-5) 抑制劑，例如他達拉非和Sildenafil，對肺動脈高壓 (PAH) 市場至關重要。這些藥物透過抑制磷酸二酯酶5發揮作用，從而擴張肺動脈並改善血流。透過特異性靶向PDE-5酶，這些抑制劑可以放鬆肺血管的平滑肌細胞，從而降低肺動脈壓力。由於PDE-5抑制劑廣泛用於治療肺動脈高壓 (PAH)，因此它們經常與聯合治療使用以提高治療效果。

在預測期內，學名藥領域預計將呈現最高的複合年成長率。

在此期間，學名藥市場呈現盈利成長，這主要得益於學名藥的普及，非專利藥可以取代品牌藥用於治療肺動脈高壓（PAH）。由於學名藥與品牌藥具有生物等效性，因此為患者提供了更經濟實惠的選擇。這提高了PAH治療的可近性，使更多患者能夠購買和服用處方藥。這些因素共同推動了該市場的成長。

市佔率最大的地區：

預計北美肺動脈高壓（PAH）市場將佔據最大佔有率。 PAH 的診斷數量正在上升，這歸功於治療方法的進步、診斷技術的改進以及公眾意識的提高。此外，北美完善的醫療保健系統和高額的醫療費用支出也擴大了患者獲得尖端治療方法和藥物的機會。製藥公司、研究機構和醫療服務提供者之間的合作也是推動北美地區 PAH 研發和推廣的關鍵因素。

複合年成長率最高的地區：

歐洲肺動脈高壓市場長期以來穩定成長。治療方法的改進以及患者和醫療專業人員對診斷意識的提高，都促進了該地區市場的成長。歐洲擁有完善的醫療基礎設施，便於病患取得這些先進的治療方法。此外，該地區製藥公司、研究機構和醫療服務提供者之間的合作，促成了新藥和治療方法的推出，進一步加速了區域市場的成長。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場公司（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 應客戶要求，我們提供主要國家和地區的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對重點公司進行基準分析。

目錄

第1章：執行摘要

第2章：引言

  • 概括
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進因素
  • 抑制因子
  • 機會
  • 威脅
  • 產品分析
  • 最終用戶分析
  • 新興市場
  • 新冠疫情的感染疾病

第4章：波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的競爭

第5章 全球肺動脈高壓市場：依產品分類

  • 內皮素受體拮抗劑
  • 可溶性鳥苷酸環化酶（sGC）促效劑
  • 磷酸二酯酶 5 (PDE-5) 抑制劑
  • 前列腺環素類似物
  • 其他產品

第6章 全球肺動脈高壓市場：依類型分類

  • 創新的
  • 學名藥
  • 品牌藥品
  • 其他類型

第7章 全球肺動脈高壓市場：依給藥途徑分類

  • 口服
  • 靜脈
  • 其他給藥途徑

第8章 全球肺動脈高壓市場：依最終用戶分類

  • 醫院
  • 零售藥房
  • 網路藥房
  • 其他最終用戶

第9章 全球肺動脈高壓市場：依地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太國家
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • UAE
    • 卡達
    • 南非
    • 其他中東和非洲國家

第10章 主要發展

  • 合約、夥伴關係、合作關係、合資企業
  • 收購與併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第11章：公司簡介

  • Actelion Pharmaceuticals ltd.
  • Bayer
  • Eli lilly and company
  • Gilead Sciences, Inc.
  • Gsk Plc
  • Hubei Gedian Humanwell Pharmaceutical Co., Ltd
  • Johnson & Johnson
  • Lupin
  • Pfizer Inc
  • Sun Pharmaceutical Industries Ltd.
  • Taizhou Tianrui Chemical Co., Ltd
  • Teva Pharmaceutical Industries Ltd.
  • United Therapeutics Corporation
  • Viatris Inc
Product Code: SMRC24719

According to Stratistics MRC, the Global Pulmonary Arterial Hypertension Market is accounted for $6.7 billion in 2026 and is expected to reach $11.8 billion by 2034 growing at a CAGR of 7.4% during the forecast period. High blood pressure in the arteries supplying blood to the lungs is a defining feature of pulmonary arterial hypertension, a rare and dangerous condition. Breathing difficulties and heart failure are some of the complications that can result from this elevated pressure in the pulmonary arteries. This market includes a variety of treatments intended to control and alleviate PAH symptoms, with the ultimate goal of enhancing patients' general health and outlook.

According to The American Journal of Managed Care, PAH is a rare disorder found in 15 to 50 persons per million within the United States and Europe. Idiopathic, heritable, and anorexigen-induced PAH make up 52.6% of all PAH cases. Usually, PAH affects women aged between 30 and 60 years.

Market Dynamics:

Driver:

Increasing prevalence of risk factors

PAH is often associated with underlying conditions such as connective tissue diseases, congenital heart defects, and liver disease, among others. As the incidence of these risk factors rises globally, so does the prevalence of PAH. Additionally, lifestyle factors such as sedentary behavior and exposure to environmental toxins contribute to the escalation of PAH cases. The aging population further amplifies the risk, as PAH is more commonly diagnosed in older individuals. This growing burden of risk factors has led to an upsurge in the number of people affected by PAH, driving the demand for innovative treatments, pharmaceutical interventions, and medical advancements.

Restraint:

High costs associated with treatment options

The high cost of available treatment options is a major barrier to the pulmonary arterial hypertension market. The cost of PAH drugs, which include phosphodiesterase-5 inhibitors, endothelin receptor antagonists, and prostacyclin analogs, can be prohibitive for patients and healthcare systems alike. Optimizing disease management is made more difficult by the complex nature of PAH diagnosis and treatment, which calls for specialized healthcare infrastructure and knowledge. These financial and practical limitations make it difficult to provide effective PAH care and emphasize the need for more readily available and reasonably priced therapeutic options.

Opportunity:

Development of innovative therapeutic approaches

The market for pulmonary arterial hypertension offers a number of opportunities, including the creation of novel treatment strategies and focused medications. Technological and scientific developments have made it possible to find new treatment approaches that are more effective in addressing the underlying causes of PAH. A larger patient pool may result from improved early diagnosis and raised awareness.

Threat:

Limited treatment options

The market for pulmonary arterial hypertension is seriously threatened by the scarcity of treatment options and the difficulty of creating efficient treatments. Because PAH is an uncommon and serious illness, developing new medications is difficult due to the disease's complex pathophysiology and the requirement for novel mechanisms of action. However, the lack of varied and focused treatment options could restrict patient options and impede the PAH market's overall expansion.

Covid-19 Impact:

The COVID-19 pandemic has influentially impacted the market. During lockdowns, patients with PAH had difficulty getting access to medical care and treatments. Patients with PAH experienced delays in diagnosis and treatment initiation due to disruptions in the healthcare system. Additionally, the pipeline of possible medications was impacted by hampered research and development efforts for novel PAH therapies. The PAH market was further strained by reallocations of healthcare resources and economic uncertainties. The pandemic's long-term effects on market dynamics and PAH management are still a worry, and solving these issues will take continued work.

The Phosphodiesterase-5 (PDE-5) Inhibitors segment is expected to be the largest during the forecast period

Phosphodiesterase-5 (PDE-5) Inhibitors segment commanded the largest share over the projected period. Phosphodiesterase-5 (PDE-5) Inhibitors like tadalafil and sildenafil are essential to the market for pulmonary arterial hypertension. These medications function by blocking the phosphodiesterase type 5 enzyme, which causes the pulmonary arteries to dilate and improve blood flow. These inhibitors lower pulmonary arterial pressure by relaxing smooth muscle cells in the pulmonary vessels by specifically targeting the PDE-5 enzyme. PDE-5 inhibitors are frequently used in combination therapy to improve treatment efficacy because they are widely used in the management of PAHs.

The generics segment is expected to have the highest CAGR during the forecast period

The generics segment is showing profitable growth over the period of time as it deals with the accessibility of generic substitutes for name-brand PAH drugs. Generic medications offer patients more affordable options since they are bioequivalent substitutes for their name-brand counterparts. This section helps make PAH therapies more accessible, which makes it possible for a larger group of patients to afford and take their prescribed drugs. These elements are boosting segments growth.

Region with largest share:

The pulmonary arterial hypertension (PAH) market in North America is expected to hold largest share. The frequency of PAH diagnoses is on the rise, which can be attributed to advances in treatment options, enhanced diagnostic methods, and increased awareness. Furthermore, more access to cutting-edge treatments and pharmaceuticals is made possible by North America's extensive healthcare system and high healthcare spending. Moreover, a major factor in the advancement of PAH research, development, and uptake in the North American region has been the cooperative efforts of pharmaceutical companies, research institutes, and healthcare providers.

Region with highest CAGR:

The European market for pulmonary arterial hypertension has grown consistently over a period of time. Improvements in treatment options, growing awareness among patients and healthcare professionals in diagnosis have all fueled market growth in the region. Europe also boasts a well-established healthcare infrastructure, facilitating the accessibility of these advanced treatments. Additionally, the collaborative efforts between pharmaceutical companies, research institutions, and healthcare organizations in the region have resulted in the introduction of novel drugs and therapies, further propelling regional growth.

Key players in the market

Some of the key players in Pulmonary Arterial Hypertension market include Actelion pharmaceuticals ltd., Bayer, Eli lilly and company, Gilead sciences, inc., Gsk plc , Hubei Gedian Humanwell Pharmaceutical Co., Ltd, Johnson & johnson , Lupin, Pfizer inc, Sun pharmaceutical industries ltd., Taizhou Tianrui Chemical Co., Ltd, Teva pharmaceutical industries ltd., United therapeutics corporation and Viatris inc.

Key Developments:

In December 2023, G+Flas Life Sciences and Bayer AG have signed a letter of intent (LOI) to collaborate on the development of novel Crispr genome-edited tomato varieties that are nutritionally enhanced with vitamin D3. This LOI underscores the shared interest of G+FLAS and Bayer AG in developing tomato seeds that not only meet high commercial standards but also incorporate cutting-edge genetic traits through G+Flas's Crispr genome editing technology.

In October 2023, Viatris Inc., a global healthcare company, announced it has received an offer for the divestiture of substantially all of its Over-the-Counter (OTC) business, and has entered into definitive agreements to divest its Women's Healthcare business. With this announcement the Company has delivered on its commitment to announce agreements on all planned divestitures by the end of 2023 within the Company's previously communicated range, after considering the estimated retained value.

Products Covered:

  • Endothelin Receptor Antagonists
  • Soluble Guanylate Cyclase (SGC) Stimulators
  • Phosphodiesterase-5 (PDE-5) Inhibitors
  • Prostacyclin Analogs
  • Other Products

Types Covered:

  • Innovative
  • Generics
  • Branded
  • Other Types

Route of Administrations Covered:

  • Oral
  • Intravenous/ subcutaneous
  • Other Routes of Administrations

End Users Covered:

  • Hospitals
  • Retail Pharmacies
  • Online Pharmacies
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Pulmonary Arterial Hypertension Market, By Product

  • 5.1 Introduction
  • 5.2 Endothelin Receptor Antagonists
  • 5.3 Soluble Guanylate Cyclase (sGC) Stimulators
  • 5.4 Phosphodiesterase-5 (PDE-5) Inhibitors
  • 5.5 Prostacyclin Analogs
  • 5.6 Other Products

6 Global Pulmonary Arterial Hypertension Market, By Type

  • 6.1 Introduction
  • 6.2 Innovative
  • 6.3 Generics
  • 6.4 Branded
  • 6.5 Other Types

7 Global Pulmonary Arterial Hypertension Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Oral
  • 7.3 Intravenous
  • 7.4 Other Routes of Administrations

8 Global Pulmonary Arterial Hypertension Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals
  • 8.3 Retail Pharmacies
  • 8.4 Online Pharmacies
  • 8.5 Other End Users

9 Global Pulmonary Arterial Hypertension Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Actelion Pharmaceuticals ltd.
  • 11.2 Bayer
  • 11.3 Eli lilly and company
  • 11.4 Gilead Sciences, Inc.
  • 11.5 Gsk Plc
  • 11.6 Hubei Gedian Humanwell Pharmaceutical Co., Ltd
  • 11.6 Johnson & Johnson
  • 11.8 Lupin
  • 11.9 Pfizer Inc
  • 11.10 Sun Pharmaceutical Industries Ltd.
  • 11.11 Taizhou Tianrui Chemical Co., Ltd
  • 11.12 Teva Pharmaceutical Industries Ltd.
  • 11.13 United Therapeutics Corporation
  • 11.14 Viatris Inc

List of Tables

  • Table 1 Global Pulmonary Arterial Hypertension Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Pulmonary Arterial Hypertension Market Outlook, By Product (2023-2034) ($MN)
  • Table 3 Global Pulmonary Arterial Hypertension Market Outlook, By Endothelin Receptor Antagonists (2023-2034) ($MN)
  • Table 4 Global Pulmonary Arterial Hypertension Market Outlook, By Soluble Guanylate Cyclase (sGC) Stimulators (2023-2034) ($MN)
  • Table 5 Global Pulmonary Arterial Hypertension Market Outlook, By Phosphodiesterase-5 (PDE-5) Inhibitors (2023-2034) ($MN)
  • Table 6 Global Pulmonary Arterial Hypertension Market Outlook, By Prostacyclin Analogs (2023-2034) ($MN)
  • Table 7 Global Pulmonary Arterial Hypertension Market Outlook, By Other Products (2023-2034) ($MN)
  • Table 8 Global Pulmonary Arterial Hypertension Market Outlook, By Type (2023-2034) ($MN)
  • Table 9 Global Pulmonary Arterial Hypertension Market Outlook, By Innovative (2023-2034) ($MN)
  • Table 10 Global Pulmonary Arterial Hypertension Market Outlook, By Generics (2023-2034) ($MN)
  • Table 11 Global Pulmonary Arterial Hypertension Market Outlook, By Branded (2023-2034) ($MN)
  • Table 12 Global Pulmonary Arterial Hypertension Market Outlook, By Other Types (2023-2034) ($MN)
  • Table 13 Global Pulmonary Arterial Hypertension Market Outlook, By Route of Administration (2023-2034) ($MN)
  • Table 14 Global Pulmonary Arterial Hypertension Market Outlook, By Oral (2023-2034) ($MN)
  • Table 15 Global Pulmonary Arterial Hypertension Market Outlook, By Intravenous (2023-2034) ($MN)
  • Table 16 Global Pulmonary Arterial Hypertension Market Outlook, By Other Routes of Administrations (2023-2034) ($MN)
  • Table 17 Global Pulmonary Arterial Hypertension Market Outlook, By End User (2023-2034) ($MN)
  • Table 18 Global Pulmonary Arterial Hypertension Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 19 Global Pulmonary Arterial Hypertension Market Outlook, By Retail Pharmacies (2023-2034) ($MN)
  • Table 20 Global Pulmonary Arterial Hypertension Market Outlook, By Online Pharmacies (2023-2034) ($MN)
  • Table 21 Global Pulmonary Arterial Hypertension Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 22 North America Pulmonary Arterial Hypertension Market Outlook, By Country (2023-2034) ($MN)
  • Table 23 North America Pulmonary Arterial Hypertension Market Outlook, By Product (2023-2034) ($MN)
  • Table 24 North America Pulmonary Arterial Hypertension Market Outlook, By Endothelin Receptor Antagonists (2023-2034) ($MN)
  • Table 25 North America Pulmonary Arterial Hypertension Market Outlook, By Soluble Guanylate Cyclase (sGC) Stimulators (2023-2034) ($MN)
  • Table 26 North America Pulmonary Arterial Hypertension Market Outlook, By Phosphodiesterase-5 (PDE-5) Inhibitors (2023-2034) ($MN)
  • Table 27 North America Pulmonary Arterial Hypertension Market Outlook, By Prostacyclin Analogs (2023-2034) ($MN)
  • Table 28 North America Pulmonary Arterial Hypertension Market Outlook, By Other Products (2023-2034) ($MN)
  • Table 29 North America Pulmonary Arterial Hypertension Market Outlook, By Type (2023-2034) ($MN)
  • Table 30 North America Pulmonary Arterial Hypertension Market Outlook, By Innovative (2023-2034) ($MN)
  • Table 31 North America Pulmonary Arterial Hypertension Market Outlook, By Generics (2023-2034) ($MN)
  • Table 32 North America Pulmonary Arterial Hypertension Market Outlook, By Branded (2023-2034) ($MN)
  • Table 33 North America Pulmonary Arterial Hypertension Market Outlook, By Other Types (2023-2034) ($MN)
  • Table 34 North America Pulmonary Arterial Hypertension Market Outlook, By Route of Administration (2023-2034) ($MN)
  • Table 35 North America Pulmonary Arterial Hypertension Market Outlook, By Oral (2023-2034) ($MN)
  • Table 36 North America Pulmonary Arterial Hypertension Market Outlook, By Intravenous (2023-2034) ($MN)
  • Table 37 North America Pulmonary Arterial Hypertension Market Outlook, By Other Routes of Administrations (2023-2034) ($MN)
  • Table 38 North America Pulmonary Arterial Hypertension Market Outlook, By End User (2023-2034) ($MN)
  • Table 39 North America Pulmonary Arterial Hypertension Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 40 North America Pulmonary Arterial Hypertension Market Outlook, By Retail Pharmacies (2023-2034) ($MN)
  • Table 41 North America Pulmonary Arterial Hypertension Market Outlook, By Online Pharmacies (2023-2034) ($MN)
  • Table 42 North America Pulmonary Arterial Hypertension Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 43 Europe Pulmonary Arterial Hypertension Market Outlook, By Country (2023-2034) ($MN)
  • Table 44 Europe Pulmonary Arterial Hypertension Market Outlook, By Product (2023-2034) ($MN)
  • Table 45 Europe Pulmonary Arterial Hypertension Market Outlook, By Endothelin Receptor Antagonists (2023-2034) ($MN)
  • Table 46 Europe Pulmonary Arterial Hypertension Market Outlook, By Soluble Guanylate Cyclase (sGC) Stimulators (2023-2034) ($MN)
  • Table 46 Europe Pulmonary Arterial Hypertension Market Outlook, By Phosphodiesterase-5 (PDE-5) Inhibitors (2023-2034) ($MN)
  • Table 48 Europe Pulmonary Arterial Hypertension Market Outlook, By Prostacyclin Analogs (2023-2034) ($MN)
  • Table 49 Europe Pulmonary Arterial Hypertension Market Outlook, By Other Products (2023-2034) ($MN)
  • Table 50 Europe Pulmonary Arterial Hypertension Market Outlook, By Type (2023-2034) ($MN)
  • Table 51 Europe Pulmonary Arterial Hypertension Market Outlook, By Innovative (2023-2034) ($MN)
  • Table 52 Europe Pulmonary Arterial Hypertension Market Outlook, By Generics (2023-2034) ($MN)
  • Table 53 Europe Pulmonary Arterial Hypertension Market Outlook, By Branded (2023-2034) ($MN)
  • Table 54 Europe Pulmonary Arterial Hypertension Market Outlook, By Other Types (2023-2034) ($MN)
  • Table 55 Europe Pulmonary Arterial Hypertension Market Outlook, By Route of Administration (2023-2034) ($MN)
  • Table 56 Europe Pulmonary Arterial Hypertension Market Outlook, By Oral (2023-2034) ($MN)
  • Table 57 Europe Pulmonary Arterial Hypertension Market Outlook, By Intravenous (2023-2034) ($MN)
  • Table 58 Europe Pulmonary Arterial Hypertension Market Outlook, By Other Routes of Administrations (2023-2034) ($MN)
  • Table 59 Europe Pulmonary Arterial Hypertension Market Outlook, By End User (2023-2034) ($MN)
  • Table 60 Europe Pulmonary Arterial Hypertension Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 61 Europe Pulmonary Arterial Hypertension Market Outlook, By Retail Pharmacies (2023-2034) ($MN)
  • Table 62 Europe Pulmonary Arterial Hypertension Market Outlook, By Online Pharmacies (2023-2034) ($MN)
  • Table 63 Europe Pulmonary Arterial Hypertension Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 64 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Country (2023-2034) ($MN)
  • Table 65 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Product (2023-2034) ($MN)
  • Table 66 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Endothelin Receptor Antagonists (2023-2034) ($MN)
  • Table 67 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Soluble Guanylate Cyclase (sGC) Stimulators (2023-2034) ($MN)
  • Table 68 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Phosphodiesterase-5 (PDE-5) Inhibitors (2023-2034) ($MN)
  • Table 69 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Prostacyclin Analogs (2023-2034) ($MN)
  • Table 70 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Other Products (2023-2034) ($MN)
  • Table 71 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Type (2023-2034) ($MN)
  • Table 72 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Innovative (2023-2034) ($MN)
  • Table 73 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Generics (2023-2034) ($MN)
  • Table 74 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Branded (2023-2034) ($MN)
  • Table 75 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Other Types (2023-2034) ($MN)
  • Table 76 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Route of Administration (2023-2034) ($MN)
  • Table 77 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Oral (2023-2034) ($MN)
  • Table 78 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Intravenous (2023-2034) ($MN)
  • Table 79 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Other Routes of Administrations (2023-2034) ($MN)
  • Table 80 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By End User (2023-2034) ($MN)
  • Table 81 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 82 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Retail Pharmacies (2023-2034) ($MN)
  • Table 83 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Online Pharmacies (2023-2034) ($MN)
  • Table 84 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 85 South America Pulmonary Arterial Hypertension Market Outlook, By Country (2023-2034) ($MN)
  • Table 86 South America Pulmonary Arterial Hypertension Market Outlook, By Product (2023-2034) ($MN)
  • Table 86 South America Pulmonary Arterial Hypertension Market Outlook, By Endothelin Receptor Antagonists (2023-2034) ($MN)
  • Table 88 South America Pulmonary Arterial Hypertension Market Outlook, By Soluble Guanylate Cyclase (sGC) Stimulators (2023-2034) ($MN)
  • Table 89 South America Pulmonary Arterial Hypertension Market Outlook, By Phosphodiesterase-5 (PDE-5) Inhibitors (2023-2034) ($MN)
  • Table 90 South America Pulmonary Arterial Hypertension Market Outlook, By Prostacyclin Analogs (2023-2034) ($MN)
  • Table 91 South America Pulmonary Arterial Hypertension Market Outlook, By Other Products (2023-2034) ($MN)
  • Table 92 South America Pulmonary Arterial Hypertension Market Outlook, By Type (2023-2034) ($MN)
  • Table 93 South America Pulmonary Arterial Hypertension Market Outlook, By Innovative (2023-2034) ($MN)
  • Table 94 South America Pulmonary Arterial Hypertension Market Outlook, By Generics (2023-2034) ($MN)
  • Table 95 South America Pulmonary Arterial Hypertension Market Outlook, By Branded (2023-2034) ($MN)
  • Table 96 South America Pulmonary Arterial Hypertension Market Outlook, By Other Types (2023-2034) ($MN)
  • Table 97 South America Pulmonary Arterial Hypertension Market Outlook, By Route of Administration (2023-2034) ($MN)
  • Table 98 South America Pulmonary Arterial Hypertension Market Outlook, By Oral (2023-2034) ($MN)
  • Table 99 South America Pulmonary Arterial Hypertension Market Outlook, By Intravenous (2023-2034) ($MN)
  • Table 100 South America Pulmonary Arterial Hypertension Market Outlook, By Other Routes of Administrations (2023-2034) ($MN)
  • Table 101 South America Pulmonary Arterial Hypertension Market Outlook, By End User (2023-2034) ($MN)
  • Table 102 South America Pulmonary Arterial Hypertension Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 103 South America Pulmonary Arterial Hypertension Market Outlook, By Retail Pharmacies (2023-2034) ($MN)
  • Table 104 South America Pulmonary Arterial Hypertension Market Outlook, By Online Pharmacies (2023-2034) ($MN)
  • Table 105 South America Pulmonary Arterial Hypertension Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 106 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Country (2023-2034) ($MN)
  • Table 106 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Product (2023-2034) ($MN)
  • Table 108 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Endothelin Receptor Antagonists (2023-2034) ($MN)
  • Table 109 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Soluble Guanylate Cyclase (sGC) Stimulators (2023-2034) ($MN)
  • Table 110 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Phosphodiesterase-5 (PDE-5) Inhibitors (2023-2034) ($MN)
  • Table 111 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Prostacyclin Analogs (2023-2034) ($MN)
  • Table 112 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Other Products (2023-2034) ($MN)
  • Table 113 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Type (2023-2034) ($MN)
  • Table 114 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Innovative (2023-2034) ($MN)
  • Table 115 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Generics (2023-2034) ($MN)
  • Table 116 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Branded (2023-2034) ($MN)
  • Table 117 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Other Types (2023-2034) ($MN)
  • Table 118 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Route of Administration (2023-2034) ($MN)
  • Table 119 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Oral (2023-2034) ($MN)
  • Table 120 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Intravenous (2023-2034) ($MN)
  • Table 121 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Other Routes of Administrations (2023-2034) ($MN)
  • Table 122 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By End User (2023-2034) ($MN)
  • Table 123 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 124 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Retail Pharmacies (2023-2034) ($MN)
  • Table 125 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Online Pharmacies (2023-2034) ($MN)
  • Table 126 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Other End Users (2023-2034) ($MN)